berberine has been researched along with Parkinson Disease in 9 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Berberine (BBR) is an organic small molecule isolated from various plants that have been used in traditional Chinese medicine." | 6.52 | Therapeutic potential of berberine against neurodegenerative diseases. ( Jiang, W; Li, S; Li, X, 2015) |
| "Berberine is an isoquinoline alkaloid that has shown promise as a pharmacological treatment in PD, given its ability to modulate several molecular pathway associated with the disease." | 2.82 | Can Berberine Serve as a New Therapy for Parkinson's Disease? ( Aschner, M; Dadgostar, E; Khandan, M; Mirzaei, H; Moghanlou, M; Mohammadi, S; Parvaresh, M; Tamtaji, OR, 2022) |
| "Berberine (BBR) is an organic small molecule isolated from various plants that have been used in traditional Chinese medicine." | 2.52 | Therapeutic potential of berberine against neurodegenerative diseases. ( Jiang, W; Li, S; Li, X, 2015) |
| "One of the treatment strategies for Parkinson's disease involves the use of drugs that aim to increase dopamine levels or simulate the action of dopamine in the brain." | 1.91 | DFT, ADME studies and evaluation of the binding with HSA and MAO-B inhibitory potential of protoberberine alkaloids from Guatteria friesiana: theoretical insights of promising candidates for the treatment of Parkinson's disease. ( Costa, EV; Costa, RA; Mary, YS; S Al-Otaibi, J; Tananta, VL, 2023) |
| "Berberine is a famous alkaloid extracted from Berberis plants and has been widely used as medications and functional food additives." | 1.62 | Treatment of Parkinson's disease in Zebrafish model with a berberine derivative capable of crossing blood brain barrier, targeting mitochondria, and convenient for bioimaging experiments. ( Jin, M; Liu, K; Liu, X; Ren, Q; Shang, X; Sheng, W; Stoika, R; Tan, Z; Wang, L; Wang, R, 2021) |
| "Treatment with berberine also improved short-term memory by inhibiting apoptosis in the hippocampus." | 1.40 | Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease. ( Cho, HS; Cho, KH; Kim, CJ; Kim, M; Lee, JM; Shin, DH; Shin, MS; Yang, HJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Dadgostar, E | 1 |
| Moghanlou, M | 1 |
| Parvaresh, M | 1 |
| Mohammadi, S | 1 |
| Khandan, M | 1 |
| Aschner, M | 1 |
| Mirzaei, H | 1 |
| Tamtaji, OR | 1 |
| Li, J | 1 |
| Meng, P | 1 |
| Zhang, J | 1 |
| He, M | 1 |
| Tananta, VL | 1 |
| Costa, EV | 1 |
| Mary, YS | 2 |
| S Al-Otaibi, J | 1 |
| Costa, RA | 1 |
| Wang, Y | 1 |
| Tong, Q | 1 |
| Ma, SR | 1 |
| Zhao, ZX | 1 |
| Pan, LB | 1 |
| Cong, L | 1 |
| Han, P | 1 |
| Peng, R | 1 |
| Yu, H | 1 |
| Lin, Y | 1 |
| Gao, TL | 1 |
| Shou, JW | 1 |
| Li, XY | 1 |
| Zhang, XF | 1 |
| Zhang, ZW | 1 |
| Fu, J | 1 |
| Wen, BY | 1 |
| Yu, JB | 1 |
| Cao, X | 1 |
| Jiang, JD | 1 |
| Wang, L | 1 |
| Sheng, W | 1 |
| Tan, Z | 1 |
| Ren, Q | 1 |
| Wang, R | 1 |
| Stoika, R | 1 |
| Liu, X | 1 |
| Liu, K | 1 |
| Shang, X | 1 |
| Jin, M | 1 |
| Ribaudo, G | 1 |
| Zanforlin, E | 1 |
| Canton, M | 1 |
| Bova, S | 1 |
| Zagotto, G | 1 |
| Kim, M | 1 |
| Cho, KH | 1 |
| Shin, MS | 1 |
| Lee, JM | 1 |
| Cho, HS | 1 |
| Kim, CJ | 1 |
| Shin, DH | 1 |
| Yang, HJ | 1 |
| Jiang, W | 1 |
| Li, S | 1 |
| Li, X | 1 |
| Mo, J | 1 |
| Guo, Y | 1 |
| Yang, YS | 1 |
| Shen, JS | 1 |
| Jin, GZ | 1 |
| Zhen, X | 1 |
3 reviews available for berberine and Parkinson Disease
| Article | Year |
|---|---|
Can Berberine Serve as a New Therapy for Parkinson's Disease?
Topics: alpha-Synuclein; Autophagy; Berberine; Dopaminergic Neurons; Humans; Neurodegenerative Diseases; Oxi | 2022 |
Therapeutic potential of berberine against neurodegenerative diseases.
Topics: Alzheimer Disease; Animals; Berberine; Blood-Brain Barrier; Disease Models, Animal; Humans; Medicine | 2015 |
Recent developments in studies of l-stepholidine and its analogs: chemistry, pharmacology and clinical implications.
Topics: Berberine; Berberine Alkaloids; Dopamine; Humans; Mental Disorders; Parkinson Disease; Receptors, Do | 2007 |
1 trial available for berberine and Parkinson Disease
| Article | Year |
|---|---|
Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients.
Topics: Berberine; Gastrointestinal Microbiome; Humans; Interleukin-6; Interleukin-8; Parkinson Disease; RNA | 2022 |
5 other studies available for berberine and Parkinson Disease
| Article | Year |
|---|---|
DFT, ADME studies and evaluation of the binding with HSA and MAO-B inhibitory potential of protoberberine alkaloids from Guatteria friesiana: theoretical insights of promising candidates for the treatment of Parkinson's disease.
Topics: Berberine; Dopamine; Guatteria; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; | 2023 |
Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota.
Topics: Animals; Berberine; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Enterococcus faecalis; Entero | 2021 |
Treatment of Parkinson's disease in Zebrafish model with a berberine derivative capable of crossing blood brain barrier, targeting mitochondria, and convenient for bioimaging experiments.
Topics: Animals; Berberine; Blood-Brain Barrier; Brain; Disease Models, Animal; Dopaminergic Neurons; Dose-R | 2021 |
Preliminary studies of berberine and its semi-synthetic derivatives as a promising class of multi-target anti-parkinson agents.
Topics: Antiparkinson Agents; Berberine; Computer Simulation; Drug Evaluation, Preclinical; Humans; Magnetic | 2018 |
Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Berberine; Caspase 3; Dentate Gyrus; DNA Fragmentati | 2014 |